Logo

Nanogen Validates Fourth Protocol for its NanoChip

Nov 06, 2001

SAN FRANCISCO, Nov. 6 – Nanogen completed internal validation of a DNA-based  research protocol for the MTHFR mutation to use on the NanoChip Molecular Biology Workstation, the company announced Tuesday.

MTHFR is associated with cardiovascular disease and the pathology of thrombosis. Protocol users will have the option to further develop and validate the protocols for internal use, the company said.

This is the fourth DNA-based research protocol that the San Diego-based company has internally validated for use on the NanoChip Molecular Biology Workstation.

“We believe a key factor in the adoption of the NanoChip Workstation will be the expansion of our menu of internally validated protocols,” Randy White, CEO of Nanogen, said in a statement. 

Nanogen obtained a non-exclusive license to the MTHFR mutation from Cambridge, Mass.-based Variagenics.

Breaking News
The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.